Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...
Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...
Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...
Structure Therapeutics Inc. (NASDAQ: GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about ...
Fintel on MSN
Structure Therapeutics Inc. - Depositary Receipt (GPCR) price target increased by 10.08% to 103.82
The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to ...
We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but ...
Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...
As of Tuesday, January 13, Structure Therapeutics Inc.’s GPCR share price has surged by 6.29%, which has investors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback